In a regulatory filing, Syros Pharmaceuticals disclosed that its director Srinivas Akkaraju bought 905K shares of common stock on December 21st in a total transaction size of $4.0M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYRS:
- Biotech Alert: Searches spiking for these stocks today
- Syros Pharmaceuticals price target raised by $6 at Piper Sandler, here’s why
- Syros announces initial data from randomized SELECT-AML combination trial
- Syros Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.14)
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
